• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UBC Gets Big Boost with $125 Million Growth Equity Investment

UBC Gets Big Boost with $125 Million Growth Equity Investment

October 8, 2009
CenterWatch Staff

Maryland-based contract research organization (CRO) United BioSource Corporation (UBC) received a $125-million growth equity from Berkshire Partners LLC, a Boston-based private equity firm, to support the company’s evidence-based acquisition and service offering expansion strategy. 

Formed in 2003 by Ethan Leder and Mark Clein with $150 million in capital, UBC went on a CRO acquisition spree, rapidly growing to today’s 1,300 employees located in more than 20 countries. 

UBC partners with life sciences companies to develop and commercialize medical products globally. The company is poised for another burst of rapid growth because it is positioned to take advantage of the federal government's focus on comparative effectiveness research. 

“With this additional capital investment, we are well-positioned to continue our targeted growth strategy recognizing that over the last six years, a steady and accelerating momentum has been building among regulators, payors, physicians and patients for new requirements and standards that go beyond FDA approval and the traditional drug development process,” said Ethan Leder, CEO of United BioSource. “These demands relate to the provision of a continuous stream of evidence of product safety, economic value and medical effectiveness in the peri- and post-approval environment. UBC was created to address these challenges and the demands of the healthcare marketplace have only intensified in recent years in this respect.” 

Randy Peeler, managing director of Berkshire Partners, added, “UBC’s management team has an impressive record of successfully integrating acquisitions, creating value across business lines and servicing the world’s most progressive life sciences companies. We are excited to have a chance to partner with a clear leader and innovator in this space. We look forward to working together with UBC’s management and founding investors to help UBC capitalize on the many growth opportunities we have identified in this dynamic and demanding marketplace.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing